Nikki Jacinto
Nurse Practitioner · Durant, OKNPI 1326651118
Payments from drug & device makers
Across 142 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$671
- Novo Nordisk$282
- AstraZeneca$201
- Amgen$170
- Lilly USA, LLC$140
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$125
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,57697%
- Education$893%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $671 |
| Novo Nordisk | 14 | $282 |
| AstraZeneca | 11 | $201 |
| Amgen | 10 | $170 |
| Lilly USA, LLC | 6 | $140 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $125 |
| GSK | 8 | $125 |
| Astellas Pharma US Inc | 1 | $89 |
| Sumitomo Pharma America, Inc. | 4 | $81 |
| Exact Sciences | 5 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Alkermes, Inc. | 3 | $60 |
| Pfizer | 1 | $58 |
| Gilead | 3 | $44 |
| Boehringer Ingelheim | 2 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Merck | 2 | $29 |
| Dexcom, Inc. | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Medtronic | 2 | $29 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Novartis | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Greer Laboratories, Inc. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Vertex | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Alk-abello, Inc | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$247
How this compares
$2,665 in reported general payments places this provider in the 85th percentile of 824 nurse practitioner providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $24,411 |
| OzempicSemaglutide | 15 | $17,563 |
| VraylarCariprazine Hcl | 11 | $15,534 |
| JardianceEmpagliflozin | 19 | $11,980 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $9,251 |
| EliquisApixaban | 14 | $7,912 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $1,128 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,089 |
| Atorvastatin Calcium | 82 | $1,016 |
| Ventolin HfaAlbuterol Sulfate | 14 | $901 |
| Gabapentin | 44 | $742 |
| Levothyroxine Sodium | 60 | $555 |
| Omeprazole | 67 | $539 |
| Methylprednisolone | 54 | $442 |
| Fluticasone Propionate | 47 | $426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $125 | $24,41135 claims |
| Novo NordiskOzempic | $282 | $17,56315 claims |
| AbbVieVraylar | $671 | $15,53411 claims |
| Boehringer IngelheimJardiance | $38 | $11,98019 claims |
| AstraZenecaBreztri Aerosphere | $201 | $9,25113 claims |
| PfizerEliquis | $58 | $7,91214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 824 nurse practitioner providers in Oklahoma.
Other nurse practitioner in Durant
- Jenny GuthrieTulsa$106K
- Leah MeltonNorman$87K
- Sara GoreOklahoma City$52K
- Teisha GalleglyMoore$43K
- Stacy NewberryTulsa$28K
- Russell RoomsOklahoma City$24K
- Grant YoungOklahoma City$15K
- Monica LawsonNorman$15K
- Amanda SmallTulsa$14K
- Janelle WagnerOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.